Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production
NCT ID: NCT02747602
Last Updated: 2016-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2016-04-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the effect of a high fat diet on serum ketone body levels after administration of CT oil with a high fat breakfast versus a standard breakfast.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group ABC
AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
AC-1204
40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (standard breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (high fat breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Group BCA
caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
AC-1204
40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (standard breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (high fat breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Group CAB
caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
AC-1204
40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (standard breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (high fat breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AC-1204
40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (standard breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
caprylic triglyceride oil (high fat breakfast)
20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dose and throughout the study.
3. Body mass index (BMI) ≥ 20.0 and ≤ 30.0 kg/m2 at screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) \< the upper limit of normal and triglycerides levels \< 250 mg/dL.
5. A non-vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to first dose/dosing of study drug. A subject who has been vasectomized less than 4 months prior to study first dose/dosing must follow the same restrictions as a non-vasectomized male).
6. Subjects must agree not to donate sperm from the first dose/dosing until 90 days after dosing.
7. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.
Exclusion Criteria
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dose/dosing.
5. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, coconut oil, or soy.
6. History or presence of diverticular disease, ulcers, inflammatory bowel disease or recurrent diarrhea or gout.
7. Positive urine drug or alcohol results at screening or check-in.
8. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
9. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
10. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
11. QTc interval is \>460 msec (males) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.
12. Estimated creatinine clearance ≤80 mL/min at screening.
13. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose and throughout the study. Acetaminophen (up to 2 g per 24 hour period) and medications for the treatment of adverse events may be permitted during the study.
14. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 28 days prior to the first dose and throughout the study.
15. Is lactose intolerant.
16. Is unable to complete the critical meal (i.e., breakfast prior to dosing).
17. Donation of blood or significant blood loss within 56 days prior to the first dose.
18. Plasma donation within 7 days prior to the first dose.
19. Participation in another clinical study within 28 days prior to the first dose. The 28-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celerion
INDUSTRY
Cerecin
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geri Poss, MD
Role: PRINCIPAL_INVESTIGATOR
Celerion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Celerion, Inc
Tempe, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-16-011_BE
Identifier Type: -
Identifier Source: org_study_id